D
D. van der Heijde
Researcher at Leiden University Medical Center
Publications - 259
Citations - 18444
D. van der Heijde is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Population & Rheumatoid arthritis. The author has an hindex of 46, co-authored 258 publications receiving 16614 citations. Previous affiliations of D. van der Heijde include University of Oslo & Loyola University Medical Center.
Papers
More filters
Journal ArticleDOI
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Peter E. Lipsky,D. van der Heijde,E W St Clair,Daniel E. Furst,F. C. Breedveld,J. R. Kalden,Josef S. Smolen,M Weisman,Paul Emery,Marc Feldmann,Gregory Harriman,Ravinder Nath Maini +11 more
TL;DR: In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Journal ArticleDOI
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Joachim Listing,Nurullah Akkoc,J Brandt,Jürgen Braun,C.T. Chou,Eduardo Collantes-Estevez,Maxime Dougados,Feng Huang,Jieruo Gu,Muhammad Asim Khan,Yesim Kirazli,Walter P. Maksymowych,Herman Mielants,Inge Juul Sørensen,Salih Ozgocmen,Euthalia Roussou,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,Joachim Sieper +22 more
TL;DR: The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial spondyloarthritis in those with chronic back pain.
Journal ArticleDOI
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Nurullah Akkoc,J Brandt,C.T. Chou,Maxime Dougados,Feng Huang,Jieruo Gu,Yesim Kirazli,F. Van den Bosch,Ivana Olivieri,Euthalia Roussou,Salvatore Scarpato,Inge Juul Sørensen,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,J. Sieper +18 more
TL;DR: The new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis, particularly regarding sensitivity.
2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Jürgen Braun,R. van den Berg,Xenofon Baraliakos,H. Boehm,Ruben Burgos-Vargas,Eduardo Collantes-Estevez,Hanne Dagfinrud,B. Dijkmans,Maxime Dougados,Paul Emery,P. Geher,Mohammed Hammoudeh,Robert D. Inman,Merryn Jongkees,Muhammad Asim Khan,Uta Kiltz,Tore K Kvien,Marjatta Leirisalo-Repo,Walter P. Maksymowych,I. Olivieri,Karel Pavelka,Joachim Sieper,Ewa Stanislawska-Biernat,D. Wendling,Salih Ozgocmen,C. Van Drogen,B.J. van Royen,D. van der Heijde +27 more
TL;DR: This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010.
Journal ArticleDOI
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Laure Gossec,Josef S Smolen,Sofia Ramiro,M. de Wit,Maurizio Cutolo,Maxime Dougados,Paul Emery,Robert Landewé,Sue Oliver,Daniel Aletaha,Neil Betteridge,Jürgen Braun,G.-R. Burmester,Juan D. Cañete,Nemanja Damjanov,Oliver FitzGerald,Emma Haglund,P S Helliwell,Tore K Kvien,Rik Lories,Thomas A. Luger,Mara Maccarone,Helena Marzo-Ortega,Dennis McGonagle,Iain B. McInnes,I. Olivieri,Karel Pavelka,Georg Schett,Joachim Sieper,F. Van den Bosch,Douglas J. Veale,Jürgen Wollenhaupt,Angela Zink,D. van der Heijde +33 more
TL;DR: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.